EGFR L861Q

Loading variant…

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Esophageal Squamous Cell Carcinoma1
EGFR L861Q	Afatinib	Predictive	D	Supports Sensitivity Response	4	submitted	EID9679 This retrospective preclinical study assessed the efficacy of afatinib towards esophageal squamous cell carcinoma (ESCC) cell lines expressing EGFR L861Q mutation. In one experiment, a ESCC KYSE270 EG… (full text at CIViC) PMID 27207775 · Nakamura et al., 2016 · Open in CIViC	civic
High-Grade Glioma, NOS1
EGFR L861Q	Erlotinib	Predictive	D	Supports Sensitivity Response	3	accepted	EID4299 In an in vitro study, a Ba/F3 cell line expressing EGFR L861Q demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assesse… (full text at CIViC) PMID ·

Molecular profile

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

Esophageal Squamous Cell Carcinoma1

EGFR L861Q

Afatinib

Predictive

Supports Sensitivity Response

submitted

EID9679

This retrospective preclinical study assessed the efficacy of afatinib towards esophageal squamous cell carcinoma (ESCC) cell lines expressing EGFR L861Q mutation. In one experiment, a ESCC KYSE270 EG… (full text at CIViC)

PMID 27207775 · Nakamura et al., 2016 · Open in CIViC

civic

High-Grade Glioma, NOS1

EGFR L861Q

Erlotinib

Predictive

Supports Sensitivity Response

accepted

EID4299

In an in vitro study, a Ba/F3 cell line expressing EGFR L861Q demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assesse… (full text at CIViC)

PMID ·

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
163380	Likely pathogenic; drug response	no assertion criteria provided	0	Tyrosine kinase inhibitor response; Lung adenocarcinoma	somatic	2	Oct 28, 2006	clinvar

Variation

Clinical significance

Review status

Stars

Conditions

Origin

Submitters

Last evaluated

Source

163380

Likely pathogenic; drug response

no assertion criteria provided

Tyrosine kinase inhibitor response; Lung adenocarcinoma

somatic

Oct 28, 2006

clinvar

Lung Adenocarcinoma1
EGFR S768I OR EGFR G719A OR EGFR L861Q	Afatinib	Predictive	A	Supports Sensitivity Response	3	accepted	EID11229 In a phase 2 trial, 129 patients with lung adenocarcinoma with EGFR mutations including mutations other than exon 19 deletions or exon 21 L858R substitutions who had no more than one previous chemothe… (full text at CIViC) PMID 22452895 · Yang et al., 2012 · Open in CIViC	civic

Lung Adenocarcinoma1

EGFR S768I OR EGFR G719A OR EGFR L861Q

Afatinib

Predictive

Supports Sensitivity Response

accepted

EID11229

In a phase 2 trial, 129 patients with lung adenocarcinoma with EGFR mutations including mutations other than exon 19 deletions or exon 21 L858R substitutions who had no more than one previous chemothe… (full text at CIViC)

PMID 22452895 · Yang et al., 2012 · Open in CIViC

civic

Lung Non-Small Cell Carcinoma3
EGFR L861Q	Erlotinib	Predictive	C	Supports Sensitivity Response	—	submitted	EID4514 In a study of 1261 non-small cell lung cancer patients, 49.8% of the analyzed tumors had EGFR mutations including deletions in exon 19 (n=258), L858R (n=260), T790M (n=6) and insertions or duplication… (full text at CIViC) PMID 21531810 · Wu et al., 2011 · Open in CIViC	civic
EGFR L861Q	Gefitinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID3802 In a study, a group of 6 participants, 5 with stage IV and one with stage IIIB lung adenocarcinoma, were sequenced at EGFR exons 18 to 21. All patients had L861Q mutation and were treated with the 1st… (full text at CIViC) PMID 21531810 · Wu et al., 2011 · Open in CIViC	civic
EGFR L861Q	Osimertinib	Predictive	B	Supports Sensitivity Response	4	submitted	EID7858 In a multicenter phase II trial in Korea, patients with NSCLC harboring EGFR mutations other than the exon 19 deletion, L858R, T790M, and exon 20 insertion were treated with osimertinib. Patients who … (full text at CIViC) PMID 31825714 · Cho et al., 2020 · Open in CIViC	civic

Lung Non-Small Cell Carcinoma3

EGFR L861Q

Erlotinib

Predictive

Supports Sensitivity Response

—

submitted

EID4514

In a study of 1261 non-small cell lung cancer patients, 49.8% of the analyzed tumors had EGFR mutations including deletions in exon 19 (n=258), L858R (n=260), T790M (n=6) and insertions or duplication… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

civic

EGFR L861Q

Gefitinib

Predictive

Supports Sensitivity Response

accepted

EID3802

In a study, a group of 6 participants, 5 with stage IV and one with stage IIIB lung adenocarcinoma, were sequenced at EGFR exons 18 to 21. All patients had L861Q mutation and were treated with the 1st… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

civic

EGFR L861Q

Osimertinib

Predictive

Supports Sensitivity Response

submitted

EID7858

In a multicenter phase II trial in Korea, patients with NSCLC harboring EGFR mutations other than the exon 19 deletion, L858R, T790M, and exon 20 insertion were treated with osimertinib. Patients who … (full text at CIViC)

PMID 31825714 · Cho et al., 2020 · Open in CIViC

civic

Malignant Neoplasm1
EGFR L861Q	Erlotinib + Gefitinib + Multikinase Inhibitor AEE788Substitutes	Predictive	D	Does Not Support Sensitivity Response	2	submitted	EID5826 EGFR L861Q was expressed in Ba/F3 cells which do not contain endogenous EGFR, and conferred growth factor independance to the cells. Cells were plated and treated with 1st generation EGFR inhibitors G… (full text at CIViC) PMID 19147750 · Kancha et al., 2009 · Open in CIViC	civic

Malignant Neoplasm1

EGFR L861Q

Erlotinib + Gefitinib + Multikinase Inhibitor AEE788Substitutes

Predictive

Does Not Support Sensitivity Response

submitted

EID5826

EGFR L861Q was expressed in Ba/F3 cells which do not contain endogenous EGFR, and conferred growth factor independance to the cells. Cells were plated and treated with 1st generation EGFR inhibitors G… (full text at CIViC)

PMID 19147750 · Kancha et al., 2009 · Open in CIViC

civic

Unmapped disease1unmapped disease
EGFR L861Q	(functional)	Functional	D	Supports Gain Of Function	4	submitted	EID10070 In an in vitro study, EGFR ectodomain missense mutants (T263P, A289V, G598V, L861Q) were expressed in human immortalized astrocytes and BaF3 cells. Phosphorylation was measured via immunoblot. All ect… (full text at CIViC) PMID 17177598 · Lee et al., 2006 · Open in CIViC	civic

Unmapped disease1unmapped disease

EGFR L861Q

(functional)

Functional

Supports Gain Of Function

submitted

EID10070

In an in vitro study, EGFR ectodomain missense mutants (T263P, A289V, G598V, L861Q) were expressed in human immortalized astrocytes and BaF3 cells. Phosphorylation was measured via immunoblot. All ect… (full text at CIViC)

PMID 17177598 · Lee et al., 2006 · Open in CIViC

civic

Evidence by cancer (8 items)

Clinical significance (1)